AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab
AbbVie has teed up a small but intriguing biotech buyout after looking over the preclinical work it’s been doing in Parkinson’s disease.
The company is called Mitokinin, a Bay Area biotech spun out of the lab of UCSF’s Kevan Shokat, whose scientific explorations have formed the academic basis of a slew of startups in the biotech hub. One of Shokat’s PhD students in the lab, Nicholas Hertz, co-founded Mitokinin using their lab work on PINK1 suggesting that amping up its activity could play an important role in regulating the mitochondrial dysfunction contributing to Parkinson’s disease pathogenesis and progression.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.